Please assess the completion status of the following clinical trial:

Trial Title: Effects of Somatostatin on Liver in ADPKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of autosomal dominant polycystic kidney and liver disease~* glomerular filtration rate greater than 40 ml/min~Exclusion Criteria:~* diabetes mellitus~* proteinuria greater than 1 g/24 hours~* significant glomerular disease~* urinary tract lithiasis and infections~* symptomatic gallstones~* biliary sludge~* cancer~* pregnant women~* lactanting women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCTEOTRIDE (Type: EXPERIMENTAL): octeotride 20 mg, intramuscular injection monthly for 3 years
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (saline soluction), intramuscular injection monthly for 3 years

Based on this trial design, predict the completion outcome and termination type (if applicable).